Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.

Oral surgery, oral medicine, oral pathology and oral radiology - 1 Jul 2016

Tan Serena, Pollack Jonathan R, Kaplan Michael J, Colevas A Dimitri, West Robert B

Abstract excerpt

OBJECTIVE: Molecular characterization of ameloblastoma has indicated a high frequency of driver mutations in BRAF and SMO. Preclinical data suggest that Food and Drug Administration-approved BRAF-targeted therapies may be immediately relevant for patients with ameloblastoma positive for the BRAF V600E mutation. METHODS: A neoadjuvant treatment regime of dabrafenib was given to a patient with recurrent BRAF-mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Ameloblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Imidazoles

Share to Neoadjuvant Therapy

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 27209484
DOI: 10.1016/j.oooo.2015.12.016

Genes

BRAF
SMO

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.PMID 27209484Read ↗

Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.Semantic proximity Read ↗

Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review.Semantic proximity Read ↗

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.Semantic proximity Read ↗

Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.Semantic proximity Read ↗

Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition: A case report with 8-year clinical follow-up.Semantic proximity Read ↗

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.Semantic proximity Read ↗

Precision therapy for BRAF V600E-mutated ameloblastoma: Systematic review insights.Semantic proximity Read ↗

Targeted therapies in ameloblastomas and amelobastic carcinoma-A systematic review.Semantic proximity Read ↗

Molecular biology exploration and targeted therapy strategy of Ameloblastoma.Semantic proximity Read ↗

Activating FGFR2-RAS-BRAF mutations in ameloblastoma.Semantic proximity Read ↗

Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors.Semantic proximity Read ↗

Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.